{"id":54478,"date":"2023-03-03T15:08:43","date_gmt":"2023-03-03T14:08:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-new-clinical-evidence-on-ai-enabled-ccta-at-acc-23-wcc\/"},"modified":"2023-03-03T15:08:43","modified_gmt":"2023-03-03T14:08:43","slug":"cleerly-to-present-new-clinical-evidence-on-ai-enabled-ccta-at-acc-23-wcc","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cleerly-to-present-new-clinical-evidence-on-ai-enabled-ccta-at-acc-23-wcc\/","title":{"rendered":"Cleerly to Present New Clinical Evidence on AI-Enabled CCTA at ACC.23\/WCC"},"content":{"rendered":"
\n

\nResearch shows accuracy and effectiveness of Cleerly\u2019s personalized evaluation of heart disease<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–Cleerly<\/a>, the company creating a new standard of care for heart disease, announced it will be presenting a number of new research studies at the American College of Cardiology\u2019s Annual Scientific Session & Expo and the World Heart Federation\u2019s World Congress of Cardiology (ACC.23\/WCC) at the Ernest N. Morial Convention Center in New Orleans, LA, March 4-6. Onsite, Cleerly executives will share new clinical evidence championing the accuracy and effectiveness of using AI-enabled coronary computed tomography angiography (CCTA) to guide personalized evaluation and treatment of coronary artery disease.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are honored to be a part of ACC.23\/WCC and join the conversation on the latest science and innovation,\u201d said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. \u201cWe\u2019ll show how we are leading with clinical science and advancing our precision heart disease detection technology to help address the world\u2019s number one public health epidemic.\u201d\n<\/p>\n

\nDuring the event, Cleerly will show how quantification of coronary artery disease (CAD) burden and atherosclerotic plaque type is the strongest determinant of future risk of major adverse cardiac events (MACE). Executives will highlight proposed treatment algorithms, outlined by the Innovations in Prevention Working Group of the American College of Cardiology, that provide personalized recommendations for medical interventions based on the combination of CCTA quantification of atherosclerotic plaque burden and traditional cardiovascular risk factors from existing clinical guidelines.\n<\/p>\n

\nCleerly will present the following poster and oral abstract sessions:\n<\/p>\n